(Reuters) - British medical products maker Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million (500.4 million pounds), as it looks to boost profit margins and find new sources of growth.
Smith and Nephew will pay Osiris shareholders $19 in cash for each share they hold. Osiris shares closed at $18.88 on the Nasdaq on Monday.4
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Sai Sachin Ravikumar)